CatalystWireBeta

Sareum Holdings (SAR): Placing of 12% of the market value

This situation live

SAR Sareum Holdings

£25m · 15.0p · −46% since the first step
Dilutive fundraise
Placing of 12% of the market value
completed
RaisePlacing · £3.34 million
Of market value12.4%
Discount49% to the last close
Reaction on the day−40%

As of 28 Oct 2026 ↗

Since Oct 2023: 312 situations of this kind – completed 77%, went quiet 23%; median share price -17% six months after they opened

Every step · 5
  1. 8 Oct 2026 announced · +0% on the day – The Capital Access Window will remain in place until a further announcement is made detailing the results of the Proposed Fundraise. ↗
  2. 26 Oct 2026 announced · -40% on the day – The Company has announced a subscription of 22,807,143 new Ordinary Shares to raise approximately £3.2 million at a price of £0.14 per Subscription Share. ↗
  3. 26 Oct 2026 announced · -40% on the day – The Company intends to launch a retail offer to its existing shareholders via the Winterflood Retail Access Platform (WRAP) at the Issue Price following... ↗
  4. 27 Oct 2026 announced · -2% on the day – due to the level of demand received, the Company has decided to close the WRAP Retail Offer early ↗
  5. 28 Oct 2026 completed – The WRAP retail offer was oversubscribed and closed early, demonstrating strong support from the Company's retail shareholder base. ↗

What is happening

Sareum Holdings: Placing of 12% of the market value – completed. ['completed']

In short
Sareum raised about £3.2m at 14p via a subscription on 26 October 2026, with free 20p warrants. The WRAP retail offer at the same price raised £150,000, and AIM trading was restored on 26 October 2026. The 2 November results confirm both closed. Proceeds fund SDC-1801 to Phase 2 readiness and the neuroscience work.
Announced
8 Oct 2026 · announced · +0% on the day
Latest
28 Oct 2026 · completed · +2% on the day
Size
c.£3.2m before expenses; 22,807,143 new shares; WRAP offer up to £100k
Price
14p per share
Discount
c.49% to 27.5p close on 7 Oct 2026
Warrants
One per subscription share, 20p exercise price, three years from Admission; rebases if later cash issue is lower
Use of money
SDC-1801 to Phase 2-ready, neuroscience programme, working capital with R&D tax credits
Briefing Pro

New to Sareum Holdings? Get up to speed in 2 minutes.

What it does, how it got here, what management promised and delivered – written from its own announcements.

Get the SAR briefing →
Ask SAR Beta
Ask anything about Sareum Holdings

Answered from its own announcements and reported figures, every statement linked to its source.

From the company's own announcements. Not investment advice.

Also at Sareum Holdings 1 open
Project milestonesSDC-1801 Phase 2-enabling programme – Dosing complete; toxicology data awaited Sareum Holdings – company page →

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note